Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12645091 | 0.86 | SERPINE1 (0.44) | TTRNSD2KMT2AMAPTMEN1 | |
| SCHEMBL12645078 | 0.85 | MAPT (0.48) | KMT2AMAPT | |
| SCHEMBL13551962 | 0.83 | NSD2 (0.36) | TTRFNTAFNTBNSD2KMT2A | |
| SCHEMBL12644665 | 0.83 | TTR (0.48) | TTRNSD2KMT2AATMLMNA | |
| SCHEMBL12644244 | 0.81 | TTR (0.50) | TTRKMT2ALMNAMAPTMEN1 | |
| SCHEMBL12645085 | 0.81 | TTR (0.65) | TTRFNTAFNTBNSD2KMT2A | |
| SCHEMBL12645086 | 0.81 | TTR (0.48) | TTRFNTAFNTBNSD2KMT2A | |
| SCHEMBL12645080 | 0.81 | TTR (0.48) | TTRFNTAFNTBNSD2KMT2A | |
| SCHEMBL13552109 | 0.76 | TTR (0.58) | TTRKMT2AATMMAPTMEN1 | |
| SCHEMBL12644735 | 0.76 | TTR (0.68) | TTRKMT2AATMLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| WO-2011075210-A2 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | TTR 1/4885FNTA 94/4885FNTB 98/4885 |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | TTR 1/4885FNTA 94/4885FNTB 98/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | TTR 1/4885FNTA 94/4885FNTB 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.